Clear Search

Showing 1 result for “Tillett W.”.

July 2021

Upadacitinib In Pazienti Con Artrite Psoriasica E Risposta Inadeguata Ai Farmaci Biologici: Dati Dallo Studio Randomizzato Controllato Di Fase 3 Select-APS 2 a 56 Settimane

Rheumatol Ther. 2021;8(2):903–919

Fifty-six-week data suggest that upadacitinib could be a favourable long-term treatment option in patients with PsA who are refractory to biologic therapy.As the need for additional therapeutic agents that can effectively control disease activity continues, new data from a 56-week analysis of the oral reversible JAK1 inhibitor, upadacitinib, currently under investigation for the treatment of PsA, shows that efficacy of the drug is maintained over the duration of this study.Mease, et al. explored...

di più…